Related Experiment Video

Updated: May 24, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.1K

Giant cell arteritis - New treatment targets at the horizon

Jens Thiel1

  • 1Division of Rheumatology and Clinical Immunology, Medical University of Graz, Graz, Austria; Department of Rheumatology and Clinical Immunology, Faculty of Medicine, University of Freiburg, Freiburg/Breisgau, Germany.

Seminars in Arthritis and Rheumatism
|March 5, 2025
PubMed

Insights

Giant cell arteritis (GCA) pathogenesis is increasingly understood, revealing new therapeutic targets. Novel treatments like Janus kinase inhibitors and IL-17A blockers are being investigated for GCA.

Area of Science:

  • Immunology
  • Rheumatology
  • Pathogenesis Research

Background:

  • Giant cell arteritis (GCA) is an inflammatory condition with complex underlying mechanisms.
  • Recent research highlights the roles of clonal hematopoiesis, immune aging, and inflammation in GCA pathogenesis.
  • Dysregulated immune checkpoints are also implicated in the disease's development.

Purpose of the Study:

  • To summarize emerging insights into the pathogenesis of giant cell arteritis.
  • To identify novel therapeutic targets based on a deeper understanding of GCA pathophysiology.
  • To review the status of new treatment options currently under investigation for GCA.

Main Methods:

  • Literature review of recent studies on GCA pathogenesis.
  • Analysis of newly identified molecular and cellular pathways involved in GCA.
  • Overview of ongoing clinical trials for novel GCA therapies.

Main Results:

  • Significant advancements in understanding GCA pathogenesis.
  • Identification of clonal hematopoiesis, immune aging, and inflammation as key factors.
  • Emergence of new treatment targets, including immune checkpoints.

Conclusions:

  • New pathophysiological insights are paving the way for innovative GCA treatments.
  • Janus kinase (JAK) inhibitors and IL-17A blocking antibodies represent promising therapeutic strategies.
  • Further research and clinical trials are essential to validate these novel approaches for GCA management.
Keywords:
Clonal hematopoesisGiant cell arteritis (GCA)IL17A inhibitorsImmune checkpointJAK inhibitors

More Related Videos

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain04:49

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

65
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

6.7K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
126
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
461
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
142
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
123